Healthcare Industry News: Cook
News Release - August 1, 2018
BD Appoints Simon Campion to Interventional Segment PresidentFRANKLIN LAKES, N.J., Aug. 1, 2018 -- (Healthcare Sales & Marketing Network) -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today appointed Simon Campion as executive vice president of BD and president, BD Interventional segment, effective Sept. 4.
Campion, 47, will report to Tom Polen, president of BD, and will be responsible for the global strategic, operational and commercial performance of the three Interventional businesses. He will also be accountable for delivering the segment's innovation agenda and integration-related synergies.
"Simon is a proven leader with deep global experience, a demonstrated focus on results and unique insight and breadth across the BD Interventional segment," Polen said. "He is well prepared to drive innovation and cultural initiatives across the Peripheral Intervention, Urology and Critical Care, and Surgery businesses, while continuing to deliver growth as we integrate these businesses into BD."
Since the completion of the C. R. Bard, Inc. transaction, Campion has been serving as worldwide president of the Surgery business, leading the integration of the BD and Bard surgical platforms. Prior to the acquisition, he led Bard's Surgery business (formerly Davol division) for five years. Campion joined Bard in 2008 in Bard's Peripheral Intervention business (formerly Peripheral Vascular division) and assumed leadership roles of increased scope and responsibility in Marketing and General Management within Bard Access Systems, Bard Canada and Davol.
Campion joined Bard from Cook Medical and began his career in R&D and marketing at Boston Scientific. He holds a doctorate in Mechanical Engineering from the University of Limerick, Ireland and a Master of Business Administration from The Open University in the United Kingdom.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help improve patient outcomes, improve the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to better diagnose disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com.
Source: Becton, Dickinson
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsBD Unveils Platelet Quality Control Media to Help Reduce the Incidence of Sepsis in Patients Requiring Platelet Transfusion
BD Receives U.S. FDA Approval for First Venous Stent to Treat Iliofemoral Venous Occlusive Disease
BD Launches Ergonomic Pen Needle Technology to Help Optimize Injection Technique